Constipation and disrupted sleep are strange warning signs for a brain disease. Yet for many people who go on to develop Parkinson’s, those are the first signals the body sends, arriving up to 20 years before tremors or muscle stiffness ever appear. For a long time, nobody could explain why a neurodegenerative disease would announce itself through the gut. A growing body of research now suggests the answer involves the Parkinson’s gut bacteria connection, and it points toward treatments that look nothing like what the neurology field has traditionally explored.
Parkinson’s disease affects around 10 million people globally, and symptoms typically begin with constipation and sleep problems, up to 20 years before progressing into dementia and the debilitating loss of muscle control. Current therapies can slow symptoms but cannot stop the underlying damage. That reality has pushed researchers toward an unlikely frontier: the digestive tract.
Multiple independent research teams across different continents have now identified the same microbial fingerprints in Parkinson’s patients’ gut microbiomes, and some are running clinical trials to see whether correcting those imbalances can shift the disease’s course.
What Parkinson’s gut bacteria are actually missing
Hiroshi Nishiwaki and colleagues at Nagoya University conducted a meta-analysis of stool samples from Parkinson’s patients across multiple countries. The goal was to find patterns that held across different populations with different diets and different baseline microbiomes, making any shared findings much harder to dismiss as coincidence.
They observed a reduction in the bacterial genes responsible for synthesizing riboflavin (vitamin B2) and biotin (vitamin B7) in patients diagnosed with Parkinson’s. The same disrupted pathway appeared consistently across all the cohorts examined. Riboflavin and biotin, derived from both food and gut microbiota, have anti-inflammatory properties that may counteract the neuroinflammation seen in Parkinson’s disease.
The significance of those missing B vitamins extends beyond inflammation. “Deficiencies in polyamines and SCFAs could lead to thinning of the intestinal mucus layer, increasing intestinal permeability, both of which have been observed in Parkinson’s disease,” Nishiwaki explained. When gut bacteria cannot produce enough B2 and B7, the downstream effects weaken the physical barrier lining the intestines.
Short-chain fatty acids (SCFAs) are compounds produced when gut bacteria ferment dietary fiber. Nishiwaki’s team identified a relationship between reduced B vitamin-synthesizing genes and low levels of these compounds, which help maintain the integrity of the intestinal barrier and prevent toxins from crossing into surrounding tissue. Polyamines play a parallel role, supporting the intestinal mucus layer that acts as the gut’s first line of defence.
How a leaky gut may trigger brain damage
When the intestinal mucus layer thins, the gut becomes more permeable, meaning substances that should stay in the digestive tract can pass through the lining into surrounding tissue. Researchers suspect the weakened protective layer exposes the intestinal nervous system to more toxins – including pesticides and herbicides – which may then reach intestinal nerves.
Alpha-synuclein is the protein that clumps together in dopamine-producing brain cells in Parkinson’s patients, and its accumulation drives the slow progression toward tremors, rigidity, and cognitive decline. Nishiwaki’s team proposed that increased gut permeability contributes to abnormal aggregation of alpha-synuclein, activating immune cells in the brain and promoting long-term inflammation.
The Nagoya University findings, published in npj Parkinson’s Disease in May 2024, led Nishiwaki to propose a practical diagnostic and treatment pathway. “We could perform gut microbiota analysis on patients or conduct fecal metabolite analysis,” he explained. “Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin supplements to those with decreased levels, potentially creating an effective treatment.”
That hypothesis gets modest support from older data. A 2003 study published in the Brazilian Journal of Medical and Biological Research found that high doses of riboflavin, combined with elimination of red meat from the diet, were associated with motor function recovery in a small group of Parkinson’s patients. The study did not include a placebo group, so it could not confirm whether riboflavin itself caused the improvements, but the signal was consistent with what Nishiwaki’s team found two decades later.
Read More: Parkinson’s May Be Largely Preventable — and the Culprit Is All Around Us
The case for fecal microbiota transplants
If disrupted gut bacteria drive part of Parkinson’s disease progression, a logical next step is trying to replace those bacteria entirely. Fecal microbiota transplantation (FMT) does exactly that: stool from a carefully screened healthy donor is processed and delivered into a patient’s gut, typically via colonoscopy. The premise is that the donor’s bacterial community can re-colonize the patient’s gut and restore what’s been lost.
Multiple randomized controlled trials have now reported results for FMT in Parkinson’s disease. The Belgian GUT-PARFECT trial, led by Dr. Arnout Bruggeman at Ghent University Hospital, was a double-blind, placebo-controlled Phase 2 clinical study in which 46 Parkinson’s patients aged 50 to 65 were randomly assigned to receive FMT from a healthy donor or their own stool as a placebo. Using a patient’s own stool as placebo eliminates the psychological benefit of believing a real treatment was received.
In participants given transplants from healthy donors, motor symptom scores improved by a mean of 5.8 points after one year – significantly more than the 2.7-point improvement seen in the control group. The gains were most pronounced between the six- and twelve-month mark, suggesting the transplanted bacteria needed time to establish themselves.
What this means for patients and research
Neither the B vitamin hypothesis nor fecal transplants are ready to become standard Parkinson’s treatments. Completed trials are still small, and Phase 2 results require replication in larger, longer studies before they can change clinical practice. Results have also varied across studies, and standardization of FMT protocols remains an open question in the field. A 2025 article in Frontiers in Neuroscience reported that FMT’s safety profile was broadly acceptable across trials, with clinical trials in Belgium and China providing supporting evidence.
The gut is no longer a side note in Parkinson’s research. Digestive symptoms appear years before motor symptoms in many patients, and alpha-synuclein aggregation, intestinal inflammation, and a compromised gut barrier have all been observed in people with the disease. That positions the gut as both a potential early warning system and a therapeutic target.
For people currently living with Parkinson’s, or caring for someone who is, asking a neurologist whether gut microbiome testing is appropriate is a reasonable next step – as is asking whether any clinical trials for FMT are enrolling nearby. The Parkinson’s Foundation maintains a clinical trials page with educational information on participating in research.
The disease remains incurable, and existing treatments only manage symptoms. Clinical trials have now produced actual numbers linking gut microbiome changes to measurable motor improvements. For 10 million people worldwide, even a partial treatment that slows progression would carry real weight.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Parkinsons and the Gut-Brain Connection